MERMAID-2: Phase 3 study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy Meeting Abstract
| Authors: | Reinmuth, N.; Spigel, D.; Peters, S.; Ahn, M. J.; Tsuboi, M.; Chaft, J.; Harpole, D.; Barlesi, F.; Abbosh, C.; Mann, H.; May, R.; Dennis, P.; Swanton, C. |
| Abstract Title: | MERMAID-2: Phase 3 study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (Hybrid-Kongress) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 44 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Oct 01-04 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2021-09-01 |
| Start Page: | 252 |
| End Page: | 253 |
| Language: | English |
| ACCESSION: | WOS:000760622600469 |
| PROVIDER: | wos |
| DOI: | 10.1159/000518417 |
| Notes: | Meeting Abstract: ep17 "Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (Hybrid Congress)" -- Meeting was also presented virtually -- Source: Wos |
